[go: up one dir, main page]

CZ129597A3 - Process for preparing small particles - Google Patents

Process for preparing small particles Download PDF

Info

Publication number
CZ129597A3
CZ129597A3 CZ971295A CZ129597A CZ129597A3 CZ 129597 A3 CZ129597 A3 CZ 129597A3 CZ 971295 A CZ971295 A CZ 971295A CZ 129597 A CZ129597 A CZ 129597A CZ 129597 A3 CZ129597 A3 CZ 129597A3
Authority
CZ
Czechia
Prior art keywords
quot
small particles
preparing small
organic compounds
precipitating
Prior art date
Application number
CZ971295A
Other languages
English (en)
Inventor
Sylvan Frank
Jan Erik Lofroth
Levon Bostanian
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Publication of CZ129597A3 publication Critical patent/CZ129597A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Confectionery (AREA)
  • Soft Magnetic Materials (AREA)

Description

• ·
•Λ.
v V -i i; : . \KV . i v'.* _ i 11 :\ v • I * · • · · • m * * · • * * « * · · · • * · · • ·
• · · **» * »· * v rr. ; Iv:·?. v·:-. l·'
v,-.- ·. .L jclS Ι \\ v\ i v
i ·· O 'O I : :\ n Κ : rcy l! Iř
V
í I
Viil·"’'' - -ίΐ'ί: i. : ' i ! ΙΊ i1.'.'1, .-',V i'· \ ΪΊΜΑ Va VOC, 1 ! V C f! i í , :'a’ r:1 ·ν·! vaa r11 . nábo;;i‘-‘M: 1 ; :: ar ažan i ria i I : v-' AÍ:'t .. r: v. a i o 1 v·.' k f'. r o s ť- .-a t. ] i ’ K v T::á:; i aa i.'ar:r.lavvrr, v y ; κ v \ Μ Μ • · · • * · · * · · · • I « · Μ * · ν • · • · * · • · I * · * * ψ · · · t· É · * 'V: ν ν!·\ \
V v vkv i. i.; V Μ :ι
Vy' \·· r.' i'i\’ ;V:ííC ]: ' . \· i:· V ' V' ’ J . ;] V v;·1 ' VV vy να r i. iv . λ·· i r
I , ' 1 i. V 1 T V \ rn vy V W V V '[ V1 v :vi r u . v
VWlY vci!' 'i a V::,· ' νγνη ..jer Y'V V1 i-’!!·: ,j I ; ; ;'J ; j ' ; ; O i y! 1 Ir^" Ol1' ; : v 4
v i Ίί:'-: !iV'iřoÍ'.'b; kfvry vy 1 :'ιν':Γ n-i : ;-u'; vy k u nahrnu]o v-vvv; '-kut- lc · ji.· j i;:;·; v ..a í ; ίο vuivnoria i !v "jvΓ!r r ar' ; nu r ομΟ.Ί i: p.n; yri'n T / .nín ί í j Ϊ mi v oivrun ar u fit s.' ; ' >"*.[ \ V' -LÍTÁ' , km-rv nahrnu
• I Μ (] » * • ··· » · · • * * Μ *♦ · » * • *
Γ\ r- Γ ^ Γ: ! : i ^ 1.!1.Ji : ' 1 . !\ Γ" 1 ο Γ ·ΐλ Υ ΓΓ1 ! J . γ;· ·:. .ι ^ , <·ΊΥ j „·1 1 j_ V : [. ! Μ .1 1 U : : ί\ Υ ι * Ο ' ’ ι. V · J i - ϊτί Γ i .L J i Γ k ' ’VV : u \\' ' ip
V : \ 'V v
v VI
P t.UD \ po;·i ppi L li fJ i - ' k Ί } ťCílloho kv
lvi'
r,i Ti: ] 'P
..VVPPIPP : 11 j p; pp.i : e r o π r; i, 7 7 II II • * » • I Μ· • * · · I · · I • V Μ ** Μ ···* • I · * • · * · • « I·· · • · · • * ·* *
V'. i : 'j ά zk lir;,; i η 0:.1 Vť-· .<.· i [i-:.· v. v or ,r v pvdi.e vyveleyu je ;. :ρ· mš ·:'"Ί . .v , :W' einde r .v : ; ve které ' '-y · M '! V K .í -'!!.ě V, které j ]!'. V--i ·..! OV ,t: : j V poměrné - 1 i K : j- i ] ' O L ; V' "íl i ] kii i í I··1 . ‘ d Μ í . ;V' íí V'e j >: i :j v L V - .1 t? í íi . Μϋν. .V 'V : Τ' π Γ ; ι.·:ί |"íi" 1 , , e ÍVi W i , ! , e Γ.·1'1 T O V i", ó W V I,' >Π , í i v ; ; ;viv i <!, a ave [ -a i. t r i ! , : ’ i!: :V ?. . V . · Li V i, Cjr; 1 eiI WCI 1 V i \řV: ια 1 θ': U ů
V K.
V k
Hivvenv : V / i VeteV i.v 1 v k ;y , ve; vy i ce i :ι I o z a vn a v v c l egeervin , V’.' ; r.v i i y ! r '.v i dev :: váty ve ! ; :\w Λγ:. : opy diietkv i ve j v I tca; :>d a a : .· V , ví. i r d >.i i v··· e;Ί i e i i ·; : ·ί;γ i ; vedny a chiori. id i r'i i :.ý ·· « ·· • • • · ♦ • • ··« • • · • • f 1 • « » • « * • • ·· ·«» ♦ · ·· ·**» v I ' ι ·. τ' ' Ο !.j ί ' ; 1 : ' Ο Γ V -'XVJ; .‘t;.: jV .1 enové dor ' v-l .. o v rr> ή .v t rj v' ·;- i' i .< v s θ l i ri, V : 'jvh c i n i o ] a ·. ·Ί X Γ.·"· O i IV ! ři X č . ·. "vy o uj i X' . v j. o k .oo \ i; Lo,". Γ. 1' O-!- 1 KΊ Γ;T. , ·."i O! v.-·
ΟΙ ΟΠΊ Ί. O o:ik'.· hydrof .ilní οί'Ί, ;jok. í i.yo :í !γκο i , Γ::
V1 Oo-O
V V ] i cí J. O
ί. '..Ό V OK i ko r y jo o! ;v r ovo; i \o ! O v j Ί 1 ! J. k V O 0 v.·· 1 J t i , >!uor :'.o vysokou i'.V : .i v o ' γ v i; :v - Oy r ' i L V 1 - O i ř ! 1 V K . 1 .. V ' i J : VO : : i V J '" I I 0 : V K ' I V1, U u 0 o ! l ' ! .V ' o l i i V K i i. 0 , o u . íKU.
V V
I v · ': ·\ v i . \ ΜΛ Μ ΜΛ
V i I : i I L- 99 ·· • 99 99 9 9 * * • ·♦ · * 9 · • · • · · t · 9 • * • · • · Ψ • « * 9 999 9 * · * · • · · 9 9 99 • · • 9* M 9 9 ; ί“. ’ i i'.η, 5 r b i r a η eí·; ϊ.μ τ u
.'.Mi L 1 1 1 V xye‘ ! :y : MM'..'V : ν ,ι'.ν v .. t- r,y
MM y k v ; i v oivnira vt I M r '\ 1
Vy.M 'Kr 11.’· L \U’:i i ; íaMV1' M Ti
v .MjM·.-M f i.lílIMMi.>i '.Midi i ckb miiimmÍ MM ; mmm , k Mm I M v vc
'1 1 r
R V 1 i :i V"v *» • ·· »« • • • *· • • • t * • «·« • Φ • • · • • « · · Φ • • * ·#· * • • · • » * ♦ ·· ·· • M ·· ·· R le i' o u J Vfl I. íf! ' ť. I I I V v i ! iV : pY ' !' - : i 1 : ; : RΛ' i.;' . i 1' v i Γ' t r II; V-.lLi r ér :VTn ; V V i i V 1 1 >v rv r ·ί í R' 1' Iv í 1 1 ,
Vi'l i V1";1 .1 1ΊΟ
: V ii - * v i, i V R ' i , R : >J r v OV i IR ’’ i.;'1 i: R VR.1'."! 'V ; .: i ,.;rv :;, ;V; '1; s-.áidh
R : V Y:
I
ν ί -· ·ν
V V ' -J i u Ο Κ ’ ι Γ;· .-V\· ι »» ♦· • I · • · 9 99 • * « « · • « * · • I 99 ·«
9 • 9 1 -.Λ1 ννΓίΐΓ λ; Μ ΙΜ* I · * • · · • t * · • · • · * j: c-

Claims (1)

14 :.vv ;ii'i : V Γ\ I í’1 κ.· - r v v \·1Ί: -f ř an r. n íj h i Γ Γ V \ '1 i: 1 , i t: ·' '[ · ί ·Ί..-:i.V-i : V1;';, · · · » * · > t *· · » 4 4 · I # 4 4 44 44 4 Μ • a · • · * 4 4 · 4 · t «4 ην »4 «444 4 4 4 4 4 4 4 4 44 444 4 ! O V' '\V * i. ; η: j ' ‘ r.' k i v v·:, i : v. r η v.·. M ·· t « · • » ·*·· * « «» * « • · • • · ··· • • 1 « * • • · • t i • ft « ♦ ··* • • # • · * • · » « »· *· *
:·:ί·Γ··' - : < " ' ^··· · "ο·: Ό ο ' : "..'i _ o ook ke.r όί i·...· o' o do.-: i ý V: namokli, ' v' i i i · Ί' , ko o·'.-1 ví o.: r .1 :[: i Γ ; ’ ' !.-:ou vmí^ériy Γ '4; i 1 J i ; vy 1 iy I . Γ I C1 Ti J.í Λ k'j srfíf-r. .1 . 1 j\ I..I v\ 1 , \'V. 'KV iu' i nu. ;; .-i v>i ic:-1! 1 i ; :í· 1 i r.·irr,- l ..v' 1 < 1 r. i VOliY rlár ok ů
CZ971295A 1994-11-09 1995-11-03 Process for preparing small particles CZ129597A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation
PCT/SE1995/001302 WO1996014833A1 (en) 1994-11-09 1995-11-03 Small particle formation

Publications (1)

Publication Number Publication Date
CZ129597A3 true CZ129597A3 (en) 1997-12-17

Family

ID=20395907

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ971295A CZ129597A3 (en) 1994-11-09 1995-11-03 Process for preparing small particles

Country Status (27)

Country Link
US (1) US5780062A (cs)
EP (1) EP0788350B1 (cs)
JP (1) JP4098827B2 (cs)
KR (1) KR970706799A (cs)
CN (1) CN1165478A (cs)
AT (1) ATE213625T1 (cs)
AU (1) AU700644B2 (cs)
BR (1) BR9509720A (cs)
CA (1) CA2203512A1 (cs)
CZ (1) CZ129597A3 (cs)
DE (1) DE69525639T2 (cs)
DK (1) DK0788350T3 (cs)
EE (1) EE9700214A (cs)
ES (1) ES2173204T3 (cs)
FI (1) FI118511B (cs)
HU (1) HUT77629A (cs)
IL (1) IL115878A0 (cs)
IS (1) IS4467A (cs)
NO (1) NO971986D0 (cs)
NZ (1) NZ295497A (cs)
PL (1) PL320425A1 (cs)
PT (1) PT788350E (cs)
SE (1) SE9403846D0 (cs)
SK (1) SK55997A3 (cs)
TR (1) TR199501400A2 (cs)
WO (1) WO1996014833A1 (cs)
ZA (1) ZA959386B (cs)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US7833549B2 (en) 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
HUP0501030A3 (en) * 2000-12-22 2008-04-28 Baxter Int Method for preparing submicron particle suspensions
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
DE10117049A1 (de) * 2001-04-05 2002-10-17 Novartis Ag Zusammensetzung
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1416917B1 (en) * 2001-08-06 2007-06-27 AstraZeneca AB Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
AU2004247615B2 (en) * 2003-06-18 2008-02-21 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US9044381B2 (en) * 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
SG135189A1 (en) 2003-09-22 2007-09-28 Baxter Int High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US20050181059A1 (en) * 2003-09-30 2005-08-18 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
EP1713443A2 (en) * 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
KR20070037444A (ko) * 2004-06-15 2007-04-04 백스터 인터내셔널 인코포레이티드 고체 미립자성 치료제의 생체외 적용방법
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
CA2723470C (en) * 2007-05-07 2013-12-03 Hale Biopharma Ventures, Llc Nasal administration of benzodiazepines
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US8101274B2 (en) * 2007-06-11 2012-01-24 Spedden Richard H Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2259798B1 (en) 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
CN101278921B (zh) * 2008-06-03 2010-06-09 海南百那医药发展有限公司 盐酸托烷司琼微囊及其注射剂生产方法
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
KR20110042107A (ko) 2008-08-07 2011-04-22 바이오엑티브 써지컬, 아이엔씨. 의료 장치 및 이식물을 위한 줄기 세포 포획 및 고정화 코팅
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN102784103A (zh) * 2011-05-16 2012-11-21 中国科学院上海药物研究所 一种通过混合胶束技术制备的普罗布考纳米混悬液及其制备方法
US20140199397A1 (en) * 2011-06-10 2014-07-17 Daniel Levin Benzoyl Peroxide Microparticle Process
EP2720699B1 (en) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3294724A4 (en) * 2015-05-08 2018-11-21 Davuluri, Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
DK0788350T3 (da) 2002-04-29
CN1165478A (zh) 1997-11-19
IS4467A (is) 1997-04-21
HUT77629A (hu) 1998-06-29
NO971986L (no) 1997-04-29
TR199501400A2 (tr) 1996-06-21
WO1996014833A1 (en) 1996-05-23
NZ295497A (en) 1998-05-27
ATE213625T1 (de) 2002-03-15
FI971947A0 (fi) 1997-05-07
BR9509720A (pt) 1997-10-21
EE9700214A (et) 1998-04-15
FI118511B (fi) 2007-12-14
AU700644B2 (en) 1999-01-14
DE69525639D1 (de) 2002-04-04
KR970706799A (ko) 1997-12-01
ZA959386B (en) 1996-05-09
NO971986D0 (no) 1997-04-29
EP0788350A1 (en) 1997-08-13
JPH10508840A (ja) 1998-09-02
DE69525639T2 (de) 2002-08-29
PT788350E (pt) 2002-07-31
JP4098827B2 (ja) 2008-06-11
SK55997A3 (en) 1998-01-14
FI971947L (fi) 1997-05-07
AU3885195A (en) 1996-06-06
CA2203512A1 (en) 1996-05-23
EP0788350B1 (en) 2002-02-27
IL115878A0 (en) 1996-01-31
SE9403846D0 (sv) 1994-11-09
ES2173204T3 (es) 2002-10-16
US5780062A (en) 1998-07-14
PL320425A1 (en) 1997-09-29

Similar Documents

Publication Publication Date Title
CZ129597A3 (en) Process for preparing small particles
WO1999001416A3 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
IL107081A0 (en) Azaquinoxalines,processes for their preparation and their use
CA2191507A1 (en) Polysiloxane-polyoxyethylene-polyoxypropylene triblock copolymers and defoaming compounds containing them
DE59707456D1 (de) Verfahren zur Herstellung von wasserlöslichen Copolymerisaten aus wenigstens einem wasserlöslichen N-Vinyllactam und wenigstens einem hydrophoben Comonomeren
AU4218093A (en) New peptides derived from trifluoromethyl ketones, process for their preparation and the pharmaceutical compositions which contain them
TR200101417T2 (tr) Sefuroksim aksetil içeren kompozisyonlar.
NZ527499A (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
ES2044787A1 (es) Procedimiento para la proteccion de materiales organicos contra la degradacion por oxidacion, degradacion termica o actinica.
PL350420A1 (en) Acetylenic sulfonamide thiol tace inhibitors
AU5239999A (en) Heterocyclyl sulphonamide derivatives
WO2001064659A3 (en) Indane derivatives and their use as cell adhesion inhibitors
GR3003738T3 (cs)
ATE30158T1 (de) 5h-(1>benzopyrano(2,3-d>pyrimidin-derivate, verfahren zu deren herstellung, sowie diese enthaltende arzneimittel zur bekaempfung von gastralen und duodenalen schleimhautlaesionen.
AU3196293A (en) Heteroaryl substituted biphenylmethyl benzimidazoles
BR9809828A (pt) Auxiliar de filtro para processamento de argila.
FR2413448A1 (fr) Dispersions de pigments et leur utilisation pour pigmenter des milieux hydrophiles et hydrophobes
GB9308431D0 (en) Chemical compounds
AU3443593A (en) 4-oxo- and 4H-imidazo(5,1-C)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents
TW249802B (cs)
Gallaudet B018a/F17: Correspondence 1890 G (448-472)
Kutuk et al. Solvent effects on the solvolyses of N-benzoyl-arenesulfonimidoyl chlorides
GB2016002A (en) Amino derivatives of pyrazolo[1,5-A]S.triazine
MX9707528A (es) Derivados de 5h,10h-imidazo[1,2-a]indeno[1,2-e]pirazin-4-ona, su preparacion y los medicamentos que los contienen.
AU6042094A (en) 4-amino-2-(hetero)aryl-butanamides useful as 5-ht1a-antagonists